Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion type Assertion NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_head.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion description "[Given the accumulating evidence that Survivin, a new member of the inhibitor of apoptosis (IAP) family, is associated with both cancer progression and drug resistance, we hypothesized that Survivin plays a potentially important role in hormone therapy resistance, and that targeting of Survivin may enhance sensitivity to antiandrogen therapy in prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_provenance.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion evidence source_evidence_literature NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_provenance.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion SIO_000772 15735703 NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_provenance.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion wasDerivedFrom befree-20140225 NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_provenance.
- NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_assertion wasGeneratedBy ECO_0000203 NP504079.RA3GNU5vYYOMc6NdDEoebMEVTiSfGp9gIDvn_8a1p3Ge0130_provenance.